logo-loader
viewAdmedus Ltd

Admedus appoints Star Bright nominees as non-executive directors

Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks in China.

board room
China is an important part of Admedus’ global growth strategy

Admedus Ltd (ASX:AHZ) has appointed Lishan Zhang and Dr Yanheng Wu as non-executive directors, representing its major investor Star Bright Holding Ltd.

READ: Admedus reports $6.3 million revenues amid $12.7 million Star Bright backing

Zhang is a highly successful businesswoman and entrepreneur with a significant network in China that is expected to greatly benefit Admedus.

She is the chair of Constellation International Group Holdings Ltd., a Hong Kong-based company with multiple interests in the development of new biotechnology assets including vaccines, nanotechnology, biomedical materials and minimally invasive tumour treatments.

Dr Wu is the president and managing director of Constellation International and has a PhD in tumour immunotherapy and nanocarrier technology from The University of Queensland.

In 2016, he established Guangzhou Hearty-Care Biotechnology Ltd., a medical technology company that is now owned by Constellation International.

READ: Admedus returns to exchange and launches a $20.2 million capital raising

Admedus chief executive officer Wayne Paterson said: “I am very excited to welcome both Ms Zhang and Dr Wu to our board of directors.

“As a major investor, Star Bright’s interest is aligned with our shareholders, and they are committed to furthering the commercial and development success of Admedus.

“China is a very important market within our global growth strategy. Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks, which will be of great value.”

New joint venture in China

Constellation International is strengthening its capabilities in the research and development of medical technology and commercialising innovative products.

The company plans to build a world-class life science industry complex in Shenzhen.

It intends to form a joint venture with Admedus to help commercial operations in China and fund clinical development programs.

Quick facts: Admedus Ltd

Price: 0.09 AUD

ASX:AHZ
Market: ASX
Market Cap: $53.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read